Clinical Presentation of Fanconi Anemia in Children
Fanconi anemia in children presents with a highly variable phenotype characterized by congenital anomalies (in approximately 60-75% of cases), progressive bone marrow failure, and short stature, though up to one-third of patients may have no physical anomalies at all. 1
Congenital Anomalies and Physical Features
Skeletal Abnormalities
- Radial ray defects are the hallmark skeletal finding, including thumb hypoplasia or absence, thumb duplication, absent or hypoplastic radii, and other upper limb malformations 1, 2
- Short stature is present in approximately 75% of patients, resulting from both skeletal malformations and growth hormone deficiency 1, 3
- Additional skeletal abnormalities occur in approximately 19% of patients 3
Craniofacial and Neurologic Features
- Microcephaly is extremely common, present in approximately 93% of patients 3
- Dysmorphic facial features may be observed 1
Skin Manifestations
- Abnormal skin pigmentation, particularly café-au-lait spots, occurs in approximately 88% of patients 3
- These cutaneous findings help differentiate Fanconi anemia from other bone marrow failure syndromes 2
Organ System Involvement
- Genitourinary malformations occur in approximately 31% of patients 3
- Ophthalmic abnormalities are present in approximately 74% of patients 3
- Cardiovascular malformations occur in approximately 11% of patients 3
- Ear and hearing abnormalities are present in approximately 10% of patients 3
- Gastrointestinal system abnormalities occur in approximately 6% of patients 3
- Genital system abnormalities are present in approximately 11% of patients 3
Hematologic Manifestations
Bone Marrow Failure
- Progressive bone marrow failure develops in more than 95% of patients and is the dominant clinical feature 2
- The mean age at diagnosis of bone marrow failure is approximately 7 years (range: 1 month to 19.8 years) 3
- Approximately 40% of patients develop severe bone marrow failure by age 20 years, and 50% by age 50 years 1
- Thrombocytopenia is typically the first hematologic manifestation, presenting as the initial clinical symptom in approximately 83% of patients 3
- Progressive cytopenias (low hemoglobin, platelets, and neutrophils) may precede any physical findings 2
Malignancy Risk in Childhood
Hematologic Malignancies
- Approximately 11% of children with Fanconi anemia develop malignancy during the pediatric period 2
- Acute myeloid leukemia (AML) accounts for more than 80% of leukemias in Fanconi anemia patients 2
- The cumulative incidence of AML by age 50 is approximately 10%, while myelodysplastic syndrome (MDS) approaches 50% 1, 2
- A total of 13% of patients in large cohorts develop malignancy during follow-up (predominantly leukemia) 3
Solid Tumors
- The cumulative incidence of solid tumors by age 50 is approximately 20-30% 2
- Head and neck squamous cell carcinoma is the most common solid tumor, with a relative risk of approximately 600-fold compared to the general population 2
Genotype-Specific Severe Phenotypes
FANCD1/BRCA2 Mutations
- Patients with biallelic FANCD1/BRCA2 mutations have the most severe phenotype, with earlier onset of disease and dramatically increased malignancy risk 2, 4
- The cumulative incidence of leukemia by age 10 is approximately 80% in these patients 2
- The cumulative incidence of any malignancy by age 7 exceeds 90% 2
- These patients present with severe congenital anomalies and require modified chemotherapy and radiation protocols due to extreme sensitivity to DNA-damaging agents 4
Diagnostic Considerations
Key Clinical Clues
- The combination of radial ray defects, abnormal skin pigmentation, short stature, and progressive cytopenias should immediately prompt consideration of Fanconi anemia 2
- However, approximately 25-40% of patients have no physical anomalies at presentation, making diagnosis challenging 2
- Some patients may show atypical features including lack of apparent deformities and negative initial chromosomal breakage tests 5
Confirmatory Testing
- The gold-standard diagnostic test is chromosomal breakage assessment after exposure to diepoxybutane (DEB) or mitomycin C (MMC), which demonstrates characteristic hypersensitivity 1, 2
- Genetic testing for FANCA gene mutations and assessment of FANCD2 protein ubiquitination can aid diagnosis in atypical cases 5